Beacon Collaboration Mission Statement
The purpose of the Beacon collaboration between MedImmune, the global biologics research and development arm of AstraZeneca, and CEB, is to produce breakthrough collaborative research in BioPharmaceutical Development.
The Beacon collaboration brings together Cambridge and MedImmune’s world class BioEngineering and BioPharmaceutical researchers to identify and address fundamental questions and challenges in BioProcessing. Our joint research programme was established in 2014-15 to foster a novel collaborative culture between the University of Cambridge and the Cambridge base of one of the world's leading biologics developers with the aim that researchers at both institutions will benefit from the freedom to think creatively and differently.
The Beacon collaboration will:
• Fund and enable exciting cutting-edge science and joint publication
• Provide mutual educational and training opportunities, and access to
complementary capabilities, models and expertise
• Act as a beacon to catalyse the growth of the BioPharmaceutical development ecosystem in Cambridge and the UK
There are currently almost twenty research in the Beacon collaboration. Information about the researchers involved in each project can be found here.
The Beacon collaboration is managed though a joint management committee (JMC), and overseen by the joint steering committee (JSC).
The public version of the annual reports of the Beacon collaboration are available here.
PhD studentships and opportunities
Of particular importance, MedImmune-supported PhD studentships at the Centre for Doctoral Training in Sensor Technologies and Applications will also be advertised through the CDT's Industry Studentships page.